- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | Gain Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.12. | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data | 3 | Investing.com | ||
| 28.11. | Gain Therapeutics reicht Prospektnachtrag für Aktienangebot über 35,5 Mio. USD ein | 2 | Investing.com Deutsch | ||
| 28.11. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11. | Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 | 1 | Seeking Alpha | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Attend the 2025 Maxim Growth Summit | 4 | GlobeNewswire (USA) | ||
| 14.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 2 | GlobeNewswire (USA) | ||
| 06.10. | Gain Therapeutics meldet vorläufige Phase-1b-Daten für Parkinson-Medikament GT-02287 | 2 | Investing.com Deutsch | ||
| 06.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.10. | Gain Therapeutics reports positive early data from Parkinson's trial | 1 | Investing.com | ||
| 06.10. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders | 3 | GlobeNewswire (USA) | ||
| 23.09. | Gain Therapeutics, Inc.: Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 | 2 | GlobeNewswire (USA) | ||
| 18.09. | Gain Therapeutics extends Phase 1b Parkinson's treatment study | 3 | Investing.com | ||
| 18.09. | Gain Therapeutics, Inc.: Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease | 185 | GlobeNewswire (Europe) | Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled... ► Artikel lesen | |
| 25.08. | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock at $8 price target | 2 | Investing.com | ||
| 25.08. | BTIG lowers Gain Therapeutics stock price target to $9 on biomarker data timing | 2 | Investing.com | ||
| 12.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Gain Therapeutics GAAP EPS of -$0.19 misses by $0.02 | 1 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,44 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | 0,00 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | 0,00 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | 0,00 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,050 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,800 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,81 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 31,550 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| RECURSION PHARMACEUTICALS | 4,580 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
GAIN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.